SHINE Technologies vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
SHINE Technologies uses fusion neutron technology to produce medical isotopes; received a conditional $263M DOE loan in April 2026 to complete the Chrysalis Mo-99 facility in Janesville, WI; facility 75-80% complete.
About
SHINE Technologies is a Janesville, Wisconsin-based company that is commercializing fusion technology for practical near-term applications — starting with medical isotope production, nuclear waste characterization, and industrial component inspection. Unlike fusion energy companies pursuing electricity generation as their first market, SHINE has built a phased commercialization strategy: its fusion neutron systems produce the radioisotopes used in medical imaging and cancer treatment today, generating commercial revenue while advancing the underlying fusion technology toward energy applications.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.